Halper Sadeh LLC said it is investigating three proposed transactions for potential violations of federal securities laws and breaches of fiduciary duties owed to shareholders. The matters involve Fulcrum Therapeutics, Inc.'s merger with Slate Medicines, Inc.; Weave Communications, Inc.'s sale to Francisco Partners for $7.40 per share in cash; and Bio-Techne Corporation's sale to Merck KGaA for $73.00 per share in cash. Under the proposed Fulcrum transaction, Fulcrum shareholders are expected to own 5.0% of the combined company after closing. The firm said insiders could receive financial benefits unavailable to ordinary shareholders and that deal terms could restrict superior competing offers. Halper Sadeh is offering to discuss shareholder rights and options at no cost or obligation, with representation available on a contingent-fee basis, meaning clients would not pay out-of-pocket legal fees or expenses. On behalf of shareholders, the firm may seek higher consideration, additional disclosures and information, or other relief and benefits.